Edgewise falls after data for muscular dystrophy therapy
Source: SeekingAlpha
2025-06-26 10:20:42 ET
More on Edgewise Therapeutics
- Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint
- Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
- Edgewise Therapeutics GAAP EPS of -$0.43
- Edgewise a new buy at Guggenheim on two pipeline prospects
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
Read the full article on Seeking Alpha
For further details see:
Edgewise falls after data for muscular dystrophy therapy
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
-3.29% G/L:
$37.77 Last:
106,463 Volume:
$40 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
